major depressive disorder code - MARKETS
Healio: Arrivo Bio initiates phase 2b trial of SIRT6 activator for major depressive disorder
May 28, 2026
Healio: Arrivo Bio initiates phase 2b trial of SIRT6 activator for major depressive disorder Please provide your email address to receive an email when new articles are posted on . The clinical trial of SP-624 is expected to enroll 450 patients with major depressive disorder. The primary ...
Understanding the Context
Arrivo Bio initiates phase 2b trial of SIRT6 activator for major depressive disorder The American Journal of Managed Care: FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder